HCW Biologics (HCWB) Stock Statistics & Valuation Metrics

HCW Biologics has a market cap or net worth of $8.94M. The enterprise value is $27.89M.

HCW Biologics has 1,123,353 shares outstanding. The number of shares has decreased by -2.65% in one year.

HCW Biologics’s return on equity (ROE) is 4.43 and return on invested capital (ROIC) is -425.86%.

The current PE Ratio of HCW Biologics is -0.58. HCW Biologics’s PEG ratio is -0.06.

In the last 12 months, HCW Biologics had revenue of 2.57M and earned -30.02M in profits. Earnings per share was -0.77.

In the last 12 months, operating cash flow was -15.29M and capital expenditures -3.86M, giving a free cash flow of -19.15M billion.

HCW Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

HCW Biologics upcoming earnings date is May 8, 2025, TBA Not Confirmed.

HCW Biologics as a current ratio of 0.19, with Debt / Equity ratio of -128.42%

In the past 12 months, HCW Biologics has paid -30.02M in taxes.

HCW Biologics EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -1.31.

HCW Biologics has $998.22K in cash and marketable securities with $0.00 in debt, giving a net cash position of $11.81M billion.

Gross margin is 17.59%, with operating margin of -1148.50%, and net profit margin of -1169.70%.

The average price target for HCW Biologics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy